Drug profile

The FDA adverse-event record for Baby Aspirin

24 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Baby Aspirin. Species, reactions, and outcomes follow.

#1614 of 2,679
by report volume (all drugs)
24
adverse-event reports
37.5%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Baby Aspirin ranks #1609 of 2679 by total reports (24). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1609
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Baby Aspirin has 24 reports now versus 21 in that prior snapshot: 3 more (14.3%).

Report change
+3
Death-coded reports
+0
Death-coded share
−5.4 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Baby Aspirin changes

Signature read: Baby Aspirin's 37.5% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
24
Total Reports
9
Deaths Reported
37.5%
Death-coded share of reports

Active Ingredients

Baby Aspirin

Administration Routes

OralUnknown

Species Affected

Dog 18
Human 4
Cat 2

Most Affected Breeds

Unknown 4
Retriever - Labrador 2
Retriever - Golden 2
Beagle 2
Collie (unspecified) 1
Domestic Mediumhair 1
Corgi - Welsh Pembroke 1
Corgi (unspecified) 1
Pug 1
Terrier - Boston 1

Most Reported Reactions

Death by euthanasia 7
Diarrhoea 4
Not eating 4
Abnormal radiograph finding 3
Other abnormal test result NOS 3
Lethargy (see also Central nervous system depression in 'Neurological') 2
Bloody diarrhoea 2
Lack of efficacy - NOS 2
Emesis 2
Anorexia 2
Elevated blood urea nitrogen (BUN) 2
Elevated creatinine 2

Outcome Breakdown

Euthanized
7 (29.2%)
Recovered/Normal
6 (25.0%)
Ongoing
5 (20.8%)
Outcome Unknown
3 (12.5%)
Died
2 (8.3%)
Recovered with Sequela
1 (4.2%)

Baby Aspirin: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Baby Aspirin (#1614 of 2,679 by report volume); death-coded 37.5%. PlainBreed drug row · death-coded share stamp 37.5% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →